Exencial Wealth Advisors LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 40,873 shares of the company’s stock, valued at approximately $2,550,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ZTS. CGOV Asset Management boosted its stake in Zoetis by 2.7% in the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock valued at $12,059,000 after acquiring an additional 4,405 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in Zoetis by 46,440.1% in the first quarter. Canada Pension Plan Investment Board now owns 143,809 shares of the company’s stock valued at $7,675,000 after acquiring an additional 143,500 shares in the last quarter. Advisory Services Network LLC acquired a new stake in Zoetis in the first quarter valued at approximately $112,000. Commerzbank Aktiengesellschaft FI boosted its stake in Zoetis by 14.1% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 9,287 shares of the company’s stock valued at $496,000 after acquiring an additional 1,146 shares in the last quarter. Finally, State Treasurer State of Michigan boosted its stake in Zoetis by 90.8% in the first quarter. State Treasurer State of Michigan now owns 1,391,592 shares of the company’s stock valued at $74,269,000 after acquiring an additional 662,100 shares in the last quarter. Institutional investors own 93.31% of the company’s stock.

TRADEMARK VIOLATION WARNING: “40,873 Shares in Zoetis Inc. (ZTS) Acquired by Exencial Wealth Advisors LLC” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/06/40873-shares-in-zoetis-inc-zts-acquired-by-exencial-wealth-advisors-llc.html.

Shares of Zoetis Inc. (ZTS) traded up 0.51% on Wednesday, hitting $63.49. 857,568 shares of the company traded hands. Zoetis Inc. has a 12 month low of $46.86 and a 12 month high of $63.85. The company has a market capitalization of $31.05 billion, a PE ratio of 35.89 and a beta of 1.02. The stock’s 50-day moving average price is $61.72 and its 200-day moving average price is $58.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.53. The firm had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. Zoetis’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.49 EPS. On average, equities analysts predict that Zoetis Inc. will post $2.34 earnings per share for the current year.

Several equities research analysts have weighed in on ZTS shares. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Hilliard Lyons started coverage on shares of Zoetis in a research note on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective for the company. Deutsche Bank AG reiterated a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Argus reiterated a “buy” rating and set a $69.00 price objective (up from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research note on Friday, July 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $65.44.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.